Analysis of comprehensive genomic profiling of solid tumors with a novel assay for broad analysis in clinical diagnostics

Somatic multigene analysis by next‐generation sequencing (NGS) is routinely integrated in medical oncology for clinical decision‐making. However, with the fast‐growing number of recommended and required genes as well as pan‐cancer biomarkers, small panels have become vastly insufficient. Comprehensi...

Full description

Saved in:
Bibliographic Details
Main Authors: Guy Froyen, Pieter‐Jan Volders, Ellen Geerdens, Severine Berden, Joni Van der Meulen, Aaron De Cock, Stefanie Vermeire, Jacques Van Huysse, Marie deBarsy, Gabriela Beniuga, Wendy W. J. deLeng, Anne M. L. Jansen, Imke Demers, Zeliha Ozgur, Hendrikus Jan Dubbink, Ernst‐Jan M. Speel, Wilfred F. J. vanIJcken, Brigitte Maes
Format: Article
Language:English
Published: Wiley 2025-06-01
Series:Molecular Oncology
Subjects:
Online Access:https://doi.org/10.1002/1878-0261.13812
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849336855699390464
author Guy Froyen
Pieter‐Jan Volders
Ellen Geerdens
Severine Berden
Joni Van der Meulen
Aaron De Cock
Stefanie Vermeire
Jacques Van Huysse
Marie deBarsy
Gabriela Beniuga
Wendy W. J. deLeng
Anne M. L. Jansen
Imke Demers
Zeliha Ozgur
Hendrikus Jan Dubbink
Ernst‐Jan M. Speel
Wilfred F. J. vanIJcken
Brigitte Maes
author_facet Guy Froyen
Pieter‐Jan Volders
Ellen Geerdens
Severine Berden
Joni Van der Meulen
Aaron De Cock
Stefanie Vermeire
Jacques Van Huysse
Marie deBarsy
Gabriela Beniuga
Wendy W. J. deLeng
Anne M. L. Jansen
Imke Demers
Zeliha Ozgur
Hendrikus Jan Dubbink
Ernst‐Jan M. Speel
Wilfred F. J. vanIJcken
Brigitte Maes
author_sort Guy Froyen
collection DOAJ
description Somatic multigene analysis by next‐generation sequencing (NGS) is routinely integrated in medical oncology for clinical decision‐making. However, with the fast‐growing number of recommended and required genes as well as pan‐cancer biomarkers, small panels have become vastly insufficient. Comprehensive genomic profiling (CGP) is, thus, required to screen for clinically relevant markers. In this multicentric study, we report on an extensive analysis across seven centers comparing the results of the novel OncoDEEP CGP assay with the diagnostically validated TruSight Oncology 500 (TSO500) kit on 250 samples. Overall concordance was 90% for clinically relevant gene variants and >96% for more complex biomarkers. Agreement for fusion detection was 94% for the 11 overlapping clinically actionable driver genes. The higher coverage uniformity of OncoDEEP compared to TSO500 allows users to pool more samples per sequencing run. Tertiary data analysis, including reporting, is integrated in the OncoDEEP solution, whereas this is an add‐on for TSO500. Finally, we showed that, analytically, the OncoDEEP panel performs well, thereby advocating its use for CGP of solid tumors in diagnostic laboratories, providing an all‐in‐one solution for optimal patient management.
format Article
id doaj-art-568ae17c42ee4fdf91b9ab88fc830551
institution Kabale University
issn 1574-7891
1878-0261
language English
publishDate 2025-06-01
publisher Wiley
record_format Article
series Molecular Oncology
spelling doaj-art-568ae17c42ee4fdf91b9ab88fc8305512025-08-20T03:44:52ZengWileyMolecular Oncology1574-78911878-02612025-06-011961797181010.1002/1878-0261.13812Analysis of comprehensive genomic profiling of solid tumors with a novel assay for broad analysis in clinical diagnosticsGuy Froyen0Pieter‐Jan Volders1Ellen Geerdens2Severine Berden3Joni Van der Meulen4Aaron De Cock5Stefanie Vermeire6Jacques Van Huysse7Marie deBarsy8Gabriela Beniuga9Wendy W. J. deLeng10Anne M. L. Jansen11Imke Demers12Zeliha Ozgur13Hendrikus Jan Dubbink14Ernst‐Jan M. Speel15Wilfred F. J. vanIJcken16Brigitte Maes17Laboratory for Molecular Diagnostics, Department of Clinical Biology Jessa Hospital Hasselt BelgiumLaboratory for Molecular Diagnostics, Department of Clinical Biology Jessa Hospital Hasselt BelgiumLaboratory for Molecular Diagnostics, Department of Clinical Biology Jessa Hospital Hasselt BelgiumLaboratory for Molecular Diagnostics, Department of Clinical Biology Jessa Hospital Hasselt BelgiumDepartment of Biomolecular Medicine Ghent University Ghent BelgiumMolecular Diagnostics Ghent University Hospital (MDG) Ghent University Hospital Ghent BelgiumDepartment of Pathology AZ Sint‐Jan Brugge AV Bruges BelgiumDepartment of Pathology AZ Sint‐Jan Brugge AV Bruges BelgiumInstitute of Pathology and Genetics (IPG) Gosselies BelgiumInstitute of Pathology and Genetics (IPG) Gosselies BelgiumDepartment of Pathology University Medical Centre Utrecht The NetherlandsDepartment of Pathology University Medical Centre Utrecht The NetherlandsDepartment of Pathology Maastricht University Medical Center Maastricht The NetherlandsGenomics Core Facility Erasmus University Medical Center Rotterdam The NetherlandsDepartment of Pathology Erasmus MC Cancer Institute Rotterdam The NetherlandsDepartment of Pathology Maastricht University Medical Center Maastricht The NetherlandsGenomics Core Facility Erasmus University Medical Center Rotterdam The NetherlandsLaboratory for Molecular Diagnostics, Department of Clinical Biology Jessa Hospital Hasselt BelgiumSomatic multigene analysis by next‐generation sequencing (NGS) is routinely integrated in medical oncology for clinical decision‐making. However, with the fast‐growing number of recommended and required genes as well as pan‐cancer biomarkers, small panels have become vastly insufficient. Comprehensive genomic profiling (CGP) is, thus, required to screen for clinically relevant markers. In this multicentric study, we report on an extensive analysis across seven centers comparing the results of the novel OncoDEEP CGP assay with the diagnostically validated TruSight Oncology 500 (TSO500) kit on 250 samples. Overall concordance was 90% for clinically relevant gene variants and >96% for more complex biomarkers. Agreement for fusion detection was 94% for the 11 overlapping clinically actionable driver genes. The higher coverage uniformity of OncoDEEP compared to TSO500 allows users to pool more samples per sequencing run. Tertiary data analysis, including reporting, is integrated in the OncoDEEP solution, whereas this is an add‐on for TSO500. Finally, we showed that, analytically, the OncoDEEP panel performs well, thereby advocating its use for CGP of solid tumors in diagnostic laboratories, providing an all‐in‐one solution for optimal patient management.https://doi.org/10.1002/1878-0261.13812comprehensive genomic profiling (CGP)diagnostic assay validationnext‐generation sequencing (NGS)solid tumors
spellingShingle Guy Froyen
Pieter‐Jan Volders
Ellen Geerdens
Severine Berden
Joni Van der Meulen
Aaron De Cock
Stefanie Vermeire
Jacques Van Huysse
Marie deBarsy
Gabriela Beniuga
Wendy W. J. deLeng
Anne M. L. Jansen
Imke Demers
Zeliha Ozgur
Hendrikus Jan Dubbink
Ernst‐Jan M. Speel
Wilfred F. J. vanIJcken
Brigitte Maes
Analysis of comprehensive genomic profiling of solid tumors with a novel assay for broad analysis in clinical diagnostics
Molecular Oncology
comprehensive genomic profiling (CGP)
diagnostic assay validation
next‐generation sequencing (NGS)
solid tumors
title Analysis of comprehensive genomic profiling of solid tumors with a novel assay for broad analysis in clinical diagnostics
title_full Analysis of comprehensive genomic profiling of solid tumors with a novel assay for broad analysis in clinical diagnostics
title_fullStr Analysis of comprehensive genomic profiling of solid tumors with a novel assay for broad analysis in clinical diagnostics
title_full_unstemmed Analysis of comprehensive genomic profiling of solid tumors with a novel assay for broad analysis in clinical diagnostics
title_short Analysis of comprehensive genomic profiling of solid tumors with a novel assay for broad analysis in clinical diagnostics
title_sort analysis of comprehensive genomic profiling of solid tumors with a novel assay for broad analysis in clinical diagnostics
topic comprehensive genomic profiling (CGP)
diagnostic assay validation
next‐generation sequencing (NGS)
solid tumors
url https://doi.org/10.1002/1878-0261.13812
work_keys_str_mv AT guyfroyen analysisofcomprehensivegenomicprofilingofsolidtumorswithanovelassayforbroadanalysisinclinicaldiagnostics
AT pieterjanvolders analysisofcomprehensivegenomicprofilingofsolidtumorswithanovelassayforbroadanalysisinclinicaldiagnostics
AT ellengeerdens analysisofcomprehensivegenomicprofilingofsolidtumorswithanovelassayforbroadanalysisinclinicaldiagnostics
AT severineberden analysisofcomprehensivegenomicprofilingofsolidtumorswithanovelassayforbroadanalysisinclinicaldiagnostics
AT jonivandermeulen analysisofcomprehensivegenomicprofilingofsolidtumorswithanovelassayforbroadanalysisinclinicaldiagnostics
AT aarondecock analysisofcomprehensivegenomicprofilingofsolidtumorswithanovelassayforbroadanalysisinclinicaldiagnostics
AT stefanievermeire analysisofcomprehensivegenomicprofilingofsolidtumorswithanovelassayforbroadanalysisinclinicaldiagnostics
AT jacquesvanhuysse analysisofcomprehensivegenomicprofilingofsolidtumorswithanovelassayforbroadanalysisinclinicaldiagnostics
AT mariedebarsy analysisofcomprehensivegenomicprofilingofsolidtumorswithanovelassayforbroadanalysisinclinicaldiagnostics
AT gabrielabeniuga analysisofcomprehensivegenomicprofilingofsolidtumorswithanovelassayforbroadanalysisinclinicaldiagnostics
AT wendywjdeleng analysisofcomprehensivegenomicprofilingofsolidtumorswithanovelassayforbroadanalysisinclinicaldiagnostics
AT annemljansen analysisofcomprehensivegenomicprofilingofsolidtumorswithanovelassayforbroadanalysisinclinicaldiagnostics
AT imkedemers analysisofcomprehensivegenomicprofilingofsolidtumorswithanovelassayforbroadanalysisinclinicaldiagnostics
AT zelihaozgur analysisofcomprehensivegenomicprofilingofsolidtumorswithanovelassayforbroadanalysisinclinicaldiagnostics
AT hendrikusjandubbink analysisofcomprehensivegenomicprofilingofsolidtumorswithanovelassayforbroadanalysisinclinicaldiagnostics
AT ernstjanmspeel analysisofcomprehensivegenomicprofilingofsolidtumorswithanovelassayforbroadanalysisinclinicaldiagnostics
AT wilfredfjvanijcken analysisofcomprehensivegenomicprofilingofsolidtumorswithanovelassayforbroadanalysisinclinicaldiagnostics
AT brigittemaes analysisofcomprehensivegenomicprofilingofsolidtumorswithanovelassayforbroadanalysisinclinicaldiagnostics